Clinical Trial Results:
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular AX 250 in Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
Summary
|
|
EudraCT number |
2015-001985-25 |
Trial protocol |
GB DE ES |
Global end of trial date |
23 Jun 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Jan 2022
|
First version publication date |
11 Jan 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
250-201
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02754076 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Allievex Corporation
|
||
Sponsor organisation address |
P.O. Box 1056, Marblehead, United States, MA, 01945
|
||
Public contact |
Clinical Trials Information, Allievex Corporation, inquiries@allievex.com
|
||
Scientific contact |
Clinical Trials Information, Allievex Corporation, inquiries@allievex.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 Jun 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Jun 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the safety and tolerability of AX 250 administered to subjects with MPS IIIB by an implanted intracerebroventricular (ICV) reservoir and catheter.
To evaluate the impact of AX 250 on cognitive function in patients with MPS IIIB as assessed by development quotient (DQ).
|
||
Protection of trial subjects |
Non-pharmacological methods (distraction, iPads, movies, etc.) were used whenever possible to facilitate IMP administration. If necessary, subjects were pretreated, at the discretion of the investigator, with age-appropriate sedative medication or general anesthesia administered by a health care professional certified for pediatric sedation/anesthesia by the local institution administered approximately 30 minutes before IMP infusion according to the institution’s standard practices.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
05 Apr 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 4
|
||
Country: Number of subjects enrolled |
United Kingdom: 2
|
||
Country: Number of subjects enrolled |
Germany: 5
|
||
Country: Number of subjects enrolled |
Colombia: 2
|
||
Country: Number of subjects enrolled |
Taiwan: 1
|
||
Country: Number of subjects enrolled |
Turkey: 5
|
||
Country: Number of subjects enrolled |
United States: 3
|
||
Worldwide total number of subjects |
22
|
||
EEA total number of subjects |
9
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
22
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Subjects were screened and enrolled into study according to the inclusion and exclusion criteria listed in the protocol | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Twenty-three subjects were screened for entry into Study 250-201. One subject withdrew consent after Screening but prior to ICV device implantation; the analysis population excludes this subject. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall study period (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Blinding implementation details |
N.A
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
No
|
|||||||||||||||
Arm title
|
Stable Dose Period | |||||||||||||||
Arm description |
The Part 1 - Dose Escalation subjects and 19 subjects previously enrolled in Study 250-901 received weekly AX 250 infusions at the MTTD (300mg) for 48 weeks. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
AX 250
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
RHNAGLU-IGF2
|
|||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||
Routes of administration |
Intraventricular use
|
|||||||||||||||
Dosage and administration details |
Subjects were treated weekly with the maximum tolerated tested dose (MTTD) of 300 mg for 48 weeks by intracerebroventricular infusion.
The surgical implantation of an ICV device took place prior to the study drug administration.
|
|||||||||||||||
Arm title
|
Dose Escalation | |||||||||||||||
Arm description |
In this period, 3 subjects received at least 4 weekly doses of AX 250 at up to 3 escalating dose levels (30, 100, and 300 mg) until the maximum tolerated tested dose (MTTD) was established. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
AX 250
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
RHNAGLU-IGF2
|
|||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||
Routes of administration |
Intraventricular use
|
|||||||||||||||
Dosage and administration details |
3 subjects received at least 4 weekly doses of AX 250 at up to 3 escalating dose levels (30, 100, and 300 mg) until the maximum tolerated tested dose (MTTD) was established
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall study period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Stable Dose Period
|
||
Reporting group description |
The Part 1 - Dose Escalation subjects and 19 subjects previously enrolled in Study 250-901 received weekly AX 250 infusions at the MTTD (300mg) for 48 weeks. | ||
Reporting group title |
Dose Escalation
|
||
Reporting group description |
In this period, 3 subjects received at least 4 weekly doses of AX 250 at up to 3 escalating dose levels (30, 100, and 300 mg) until the maximum tolerated tested dose (MTTD) was established. | ||
Subject analysis set title |
250-901
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Study 250-901 is an observational study of progressive MPS IIIB symptomology in the same set of subjects.
|
|
||||||||||||||||||||||
End point title |
The rate of change in DQ score after the treatment with data for the same subjects from pre-treatment [1] | |||||||||||||||||||||
End point description |
The rate of change in DQ score after the treatment with data for the same subjects from Study pre-treatment; Change in baseline.
Cognitive DQ decline from Baseline to Week 48 was greater than that measured in 250-901 subjects. These data suggest that 48 weeks of treatment with AX 250 is not sufficient to curb cognitive impairment that begins at younger ages; further studies are needed to determine whether treatment with AX 250 for longer durations results in cognitive benefit
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
Overall Study period
|
|||||||||||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
DQ; Rate of Change; Within-subject Comparison | |||||||||||||||||||||
Statistical analysis description |
Comparison of Rate of Change of Development Quotient (DQ) vs. Study 250-901 Within-Subject Comparison Set
|
|||||||||||||||||||||
Comparison groups |
Stable Dose Period v 250-901
|
|||||||||||||||||||||
Number of subjects included in analysis |
38
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence [2] | |||||||||||||||||||||
P-value |
= 0.0545 | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||||||||
Point estimate |
-6.66
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-13.47 | |||||||||||||||||||||
upper limit |
0.15 | |||||||||||||||||||||
Variability estimate |
Standard deviation
|
|||||||||||||||||||||
Dispersion value |
13.241
|
|||||||||||||||||||||
Notes [2] - Within subject difference Mean change from Baseline to Week 48 (SD) = -6.66 (13.241) |
||||||||||||||||||||||
Statistical analysis title |
Sensitivity Analysis; Rate of Change in DQ | |||||||||||||||||||||
Statistical analysis description |
As a sensitivity analysis, the effect of treatment with AX 250 on DQ score over time will be determined from an analysis of covariance.
The effect of treatment will be summarized by LSMEANs of Treated vs. Not Treated status as of 730 days after the start of Study 250-901 (2 years, approximately the end of Study 250-201). The test for a difference between the 2 LSMEANs at Day 730 will be the test of the effect of treatment.
LS Mean at Day 730 In Treated and untreated Status = 40.586 and 45.514
|
|||||||||||||||||||||
Comparison groups |
Stable Dose Period v 250-901
|
|||||||||||||||||||||
Number of subjects included in analysis |
38
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other [3] | |||||||||||||||||||||
P-value |
= 0.0492 [4] | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
Notes [3] - The following linear model will be fit to the pooled DQ data of Study 250-901 and Study 250-201: yijk = αi + (βi * tij) + γk + εij where yijk is the DQ score for subject i at who is either being "Treated" (k=l) or "Not Treated" (k=0) at Visit j αi is the fixed intercept for Subject i βi is a fixed regression slope on tij for Subject i tij is day of Visit j in either study where Day 1 is Day 1 of Study 901 γk is a constant effect of treatment and ε j ~ N(0,σ^2). [4] - The model includes a fixed intercept for each subject, a linear slope on Day and an effect of being in Treated Status vs. Not Treated Status. Estimated Diff. LS Means: 'Treated'-'Not Treated' = -4.928 Standard Error of Estimate = 2.4881 No CI |
|
||||||||||||||||||||||
End point title |
Age equivalent score (AEq); Rate of Change of Cognitive Age Equivalent score from Baseline to Week 48 [5] | |||||||||||||||||||||
End point description |
Age Equivalent score based on BSID-III (Bayley Scales of Infant and Toddler Development, Third Edition) cognitive test or KABC-II (Kaufman Assessment Battery for Children, Second Edition) Nonverbal Index (NVI).
The majority of 250-201 subjects showed arrested, below normal cognitive development with AEq scores of 25 to 30 months at Baseline that declined from Baseline to Week 48. This trend is contrary to that seen in Study 250-901, where subjects experienced modest increases in cognitive ability from Baseline to Week 48.
Adaptive behavior AEq scores were below normal for age and declined in most treated subjects, again suggesting that 48 weeks of treatment with AX 250 is not sufficient to curb adaptive behavior impairment that begins at younger ages. Further studies are needed to determine whether treatment with AX 250 for longer durations results in adaptive behavior benefit
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
Overall study period
|
|||||||||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
AEq: Within Subject Difference; Baseline to Week48 | |||||||||||||||||||||
Statistical analysis description |
Comparison of Rate of Change of Cognitive Age Equivalent (AEq) Score vs. Study 250-901 Within-Subject Comparison Set
|
|||||||||||||||||||||
Comparison groups |
Stable Dose Period v 250-901
|
|||||||||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence [6] | |||||||||||||||||||||
P-value |
= 0.0004 | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||||||||
Point estimate |
-7.6
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-11.2 | |||||||||||||||||||||
upper limit |
-4 | |||||||||||||||||||||
Variability estimate |
Standard deviation
|
|||||||||||||||||||||
Dispersion value |
6.98
|
|||||||||||||||||||||
Notes [6] - Within subject difference Mean change from Baseline to Week 48 (SD) = -7.6 (6.98) |
||||||||||||||||||||||
Statistical analysis title |
Sensitivity Analysis of Rate of Change of AEq | |||||||||||||||||||||
Statistical analysis description |
Sensitivity Analysis of Rate of Change of Cognitive Age Equivalent (AEq) Score vs. Study 250-901 Within-Subject Comparison Set The effect of treatment will be summarized by LSMEANs of Treated vs. Not Treated status as of 730 days after the start of Study 250-901 (2 years, approximately the end of Study 250-201). The test for a difference between the 2 LSMEA at Day 730 will be the test of the effect of treatment.
|
|||||||||||||||||||||
Comparison groups |
Stable Dose Period v 250-901
|
|||||||||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
other [7] | |||||||||||||||||||||
P-value |
= 0.0237 [8] | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
Notes [7] - The following linear model will be fit to the pooled DQ data of Study 250-901 and Study 250-201: yijk = αi + (βi * tij) + γk + εij where yijk is the DQ score for subject i at who is either being "Treated" (k=l) or "Not Treated" (k=0) at Visit j αi is the fixed intercept for Subject i βi is a fixed regression slope on tij for Subject i tij is day of Visit j in either study where Day 1 is Day 1 of Study 901 γk is a constant effect of treatment and ε j ~ N(0,σ^2 [8] - LS Mean at Day 730 In Treated and Not treated Status = 29.102 and 32.124 Estimated Diff. in Treated and Not Treated LS Means = -3.021 Standard error of estimate = 1.3239 No confidence interval. |
|
|||||||||||||||||
End point title |
Maximum concentration of AX 250 detected in Plasma - Part 2 - Stable Period Dose [9] [10] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 15, 14, 14 & 15 respectively.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Time (hours) for maximum AX 250 concentration in CSF -Part 2 - Stable Period Dose [11] [12] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 16, 14, 15 & 16 respectively.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Time (hours) for maximum AX 250 concentration in Plasma -Part 2 - Stable Period Dose [13] [14] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 16, 13, 13 & 10 respectively.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Area under the AX 250 CSF concentration-time curve from time 0 to infinity - Part 2 - Stable Period Dose [15] [16] | ||||||||||
End point description |
Weeks 5, 12 and 36 values not applicable for this data set; values not entered.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||
Notes [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Area under the AX 250 Plasma concentration-time curve from time 0 to infinity - Part 2 - Stable Period Dose [17] [18] | ||||||||||
End point description |
Weeks 5, 12 and 36 values not applicable for this data set; values not entered.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||
Notes [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Area under the AX 250 CSF concentration-time curve from 0 to time of last measurable concentration - Part 2 - Stable Period Dose [19] [20] | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
AX 250 CSF: Elimination half-life - Part 2 - Stable Dose Period [21] [22] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 17, 12, 15 & 1 respectively
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
AX 250 Plasma: Elimination half-life - Part 2 - Stable Dose Period [23] [24] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 6, 3, 3 & <3 respectively. As Week 36 has <3 applicable observations, no value was calculated and reported as '0' zero value.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. t. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Clearance of AX 250 from CSF - Part 2 - Stable Dose Period [25] [26] | ||||||||||||||||
End point description |
Number of applicable observations varied over time: Week 1, 5, 12 & 36 = 17, 15, 16 & 16 respectively
Note, Week 5 mean value was affected by a single outlier value; Median value = 17.4ml/h
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Clearance of AX 250 from Plasma - Part 2 - Stable Dose Period [27] [28] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 6, 13, 13 & 11 respectively
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Apparent volume of distribution in CSF of AX 250 - Part 2- Stable Dose Period [29] [30] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 6, 3, 3 & >3 respectively
As Week 36 has <3 applicable observations, no value was calculated and reported as '0' zero value.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2- Stable Dose Period
|
||||||||||||||||
Notes [29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
RCmax: Accumulation ratio (in percent) for Cmax of AX 250 in CSF - Part 2 - Stable Dose Period [31] [32] | ||||||||||||||||
End point description |
Week 1 not applicable in this instance, and therefore not tabulated.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
RCmax: Accumulation ratio (in percent) for Cmax of AX 250 in Plasma - Part 2 - Stable Dose Period [33] [34] | ||||||||||||||||
End point description |
Week 1 not applicable in this instance, and therefore not tabulated.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
RAUC(0-τ) accumulation ratio (in percent) for AUC(0-τ) for AX 250 in CSF [35] [36] | ||||||||||||||||
End point description |
Week 1 not applicable in this instance, and therefore not tabulated.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
RAUC(0-τ) accumulation ratio (in percent) for AUC(0-τ) for AX 250 in Plasma [37] [38] | ||||||||||||||||
End point description |
Week 1 not applicable in this instance, and therefore not tabulated.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
PCRatioCmax plasma to CSF ratio (in percent) for Cmax [39] [40] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 15, 14, 13 & 15 respectively
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
PC Ratio AUC(0-τ) plasma to CSF ratio (in percent) for AUC(0-τ) [41] [42] | ||||||||||||||||
End point description |
Week 1 not applicable in this instance, and therefore not tabulated.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Dose Period
|
||||||||||||||||
Notes [41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. [42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Maximum concentration of AX 250 detected in CSF - Part 2 - Stable Period Dose [43] | ||||||||||||||||
End point description |
Number of applicable observations varies across the categories: Week 1,5,12 & 36 = 16,14,15 & 16 respectively.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Area under the AX 250 Plasma concentration-time curve from 0 to time of last measurable concentration - Part 2 - Stable Period Dose [44] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 15, 14, 14 & 16 respectively
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Part 2 - Stable Period Dose
|
||||||||||||||||
Notes [44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Apparent volume of distribution in Plasma of AX 250 - Part 2- Stable Dose Period [45] | ||||||||||||||||
End point description |
Number of applicable observations varies over time: Week 1, 5, 12 & 36 = 6, 3, 3 & <3 respectively. As Week 36 has <3 applicable observations, no value was calculated and reported as '0' zero value.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Part-2
|
||||||||||||||||
Notes [45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This is a pharmacokinetic parameter, no statistical analysis planned for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Overall Study Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Participants of Part 1 and Part 2 are combined under 'Group Part 2' in the reporting of AEs
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Stable Dose Period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The Part 1 - Dose Escalation subjects and 19 subjects previously enrolled in Study 250-901 received weekly AX 250 infusions at the MTTD (300mg) for 48 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
28 Oct 2015 |
Amendment 1
Date: 28 October 2015
RATIONALE AND SUMMARY OF MAJOR CHANGES
The major changes and rationale for amending Protocol 250-201 (original protocol) are as
follows:
1. In the original protocol, Section 9.3.3.1 (Stopping Criteria) provided guidance on the disposition of subjects who experience unacceptable drug-related toxicity.
2. In the original protocol, Section 9.4.4.1 (Safety Monitoring) provided guidance on monitoring infusions
|
||
11 Jun 2017 |
Amendment 2
Date: 1 June 2017
A summary of major changes covered by Amendment 2 to the 250-201 protocol is provided
below:
1. CSF glucose measurements have been added to the intensive sampling of CSF for GAG and PK analysis.
2. Language has been added to improve the monitoring of neurological symptoms during Part 2 of the study in three ways as detailed in the Protocol
3. Details concerning the use of an independent Data Monitoring Committee (DMC) during Part 2 of the study have been added.
4. It has been clarified that, for Part 2 of the study, pre-ICV placement imaging could be either a CT scan or an MRI, but that such a scan is mandatory.
5. Text has been added requesting that, as much as possible, subjects keep a consistent antipsychotic medication regimen during the study, and that an attempt should be made prior to enrollment to ensure that the subject is receiving a stable antipsychotic medication regimen.
6. Language has been added to clarify that sedatives and general anesthesia should be given to aid in BMN 250 dosing only when absolutely necessary. The use of sedation should be minimized in favor of distraction techniques.
7. Evaluation of the impact of BMN 250 on cognitive function in patients with MPS IIIB as assessed by age equivalent score (AEq) has been added as a secondary efficacy variable.
8. The Part 2 Baseline, Week 24, and Week 48 visits may occur over 2-3 days (rather than 3 days).
9. The Parenting Stress Index (PSI) has been removed as an outcome measure.
10. Anti-BMN250 total antibodies (TAb) and neutralizing antibodies (NAb) in CSF and anti-BMN250 TAb in serum will be measured at Week 2 of Part 2 in all subjects.
11. Hypoglycemia-specific stopping criteria have been added.
12. Language around the age requirements for enrollment has been modified for clarity.
13. To correct an inconsistency in previous versions of the protocol, the Vineland Adaptive Behavior Scales,
14. The identity of the Medical Monitor has been changed. |
||
11 Sep 2017 |
Amendment 3
Date: 11 September 2017
A summary of major changes covered by Amendment 3 to the 250-201 protocol is provided
below:
1. Cell count and protein were added as analyses to be performed on cerebrospinal fluid
(CSF) samples already collected 4, 10, 24, 48, 72, and 96 hours post-dose as part of serial
PK analyses at Part 2 Baseline and Weeks 5, 12, and 36.
2. Glycosaminoglycans (GAGs) were removed from analyses to be performed on CSF
samples collected 4, 10, 24, 48, and 96 hours post-dose as part of serial PK analyses at
Part 2 Baseline and Weeks 5, 12, and 36.
3. Section 12.2.4 (Part 2 Treatment Visits) has been amended with the addition of a bowel
habits questionnaire to be administered by the site staff at Part 2 Baseline and every
4 weeks thereafter.
4. Section 12.2.4 (Part 2 Treatment Visits) has been amended to specify that for subjects
below 14.3 kg in weight at the 250-201 Part 2 Baseline, blood normally collected for
exploratory analyses will not be drawn at Week 4 or Week 8.
5. Section 9.3.3.1 (Stopping Criteria) has been amended. This change strengthens trial subject safety monitoring by more clearly defining BioMarin actions and DMC involvement in the face of potential treatment-related SAEs.
6. Language has been added in Section 9.4.6 (Selection of Doses Used in the Study) to allow for dose reductions in individual subjects should they experience serious treatment-related adverse events.
7. Language has been added to Section 9.3.4 (Subject Identification and Replacement of
Subjects) stating, “Subjects previously enrolled in Study 250-901 before enrolling
into Part 2 of this study will receive a new subject ID for the 250-201 study.”
Additional major changes listed within Summary of Changes documentation. |
||
06 Dec 2019 |
Amendment 4
Date: 06 December 2019
A summary of major changes covered by Amendment 4 to the 250-201 protocol is provided below:
Sponsor change from BioMarin Pharmaceutical Inc to Allievex Corporation |
||
31 Jan 2020 |
Amendment 5
Date: 31 January 2020
A summary of the major changes in Amendment 5 of the 250-201 protocol is provided below:
1. Brain imaging (MRI or CT) should be performed up to Q4W to monitor for asymptomatic subdural hygroma formation.
2. Immediate pre-infusion, immediate post-infusion and 24 hour post-infusion brain imaging (MRI or CT) will be performed up to once for each patient.
3. The amount of CSF withdrawn prior to administering AX 250 has been changed from “10mL” to “up to 10mL”.
4. BMN 250 is now referred to as AX 250.
5. The contact information for Pharmacovigilance has been updated consistent with the change in sponsor from BioMarin to Allievex.
6. For the Children’s Sleep Health Questionnaire (CSHQ), 3 additional subscale scores (sleep initiation, sleep distress, and sleep transition) based on regrouping of item scores on the standard CSHQ are added to the score outputs.
7. Mentions of a version of the CSHQ adapted by researchers at the University of Minnesota were removed from the protocol.
8. Change to language in Appendix 1; These changes clarify how subjects who score below the range at which the KABC can accurately determine age equivalent scores will be evaluated at subsequent study visits. This ensures that cognitive test data will be as accurate as possible.
9. Nonclinical study data have been updated.
10. The Summary of Overall Risks and Benefits (Section 7.4) has been updated.
11. Minor changes have been made for purposes of clarity and consistency. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |